A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Required: CCNE1 protein overexpression (positive Cyclin E1 protein status by IHC using Sponsor's assay)

Tumor testing (archival acceptable) confirms a positive Cyclin E1 protein status result determined by IHC using the Sponsor's investigational clinical trial assay

Must have received: bevacizumab (bevacizumab) — if eligible per standard of care

Prior bevacizumab treatment is required, if eligible per standard of care

Must have received: PARP inhibitor — if BRCA 1/2 mutation or HRD, if eligible per standard of care

Prior PARP inhibitor treatment is required if BRCA 1/2 mutation or HRD, if eligible per standard of care

Must have received: mirvetuximab (mirvetuximab) — if eligible per standard of care

Prior mirvetuximab treatment is required, if eligible per standard of care

Cannot have received: WEE1 inhibitor (ZN-c3)

Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.

Cannot have received: ATR inhibitor

Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.

Cannot have received: PKMYT1 inhibitor

Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.

Cannot have received: CHK1/2 inhibitor

Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, PKMYT1 inhibitor, or CHK1/2 inhibitor.